openPR Logo
Press release

greenovation launches Bryo-Speed™ and Bryo-Master™ for the production of therapeutical proteins

11-01-2007 01:27 PM CET | Health & Medicine

Press release from: greenovation Biotech GmbH

/ PR Agency: trio-financial relations AG
From pilot study to stable production: in Bryo-Speed™ and Bryo-Master™ greenovation presents a production platform for custom-made pharmaceuticals – Presentation of the new products at BioProduction 2007 in Berlin

Heilbronn/ Germany – November 1st 2007 – Bryo-Speed™ and Bryo-Master™ are greenovation’s innovative production systems for the effective optimization and creation of pharmaceutically highly efficient glycoproteins: The production platform is based on bryotechnology which has been developed by greenovation and enables the genetic modification of mosses in a contained photo bioreactor in a way that they reproduce exactly the desired therapeutic protein – for example a cancer-fighting antibody – according to a given blueprint. Yesterday the company seated in Heilbronn introduced their product innovation at a separate event within the trade fair BioProduction 2007 in Berlin to an interested expert audience. With their innovative technology greenovation owns a unique processing system for developing and producing a new generation of customized pharmaceuticals.

greenovation’s Bryo-Speed™ can produce a customized high quality glycoprotein in low quantities according to the specifications of customers within a time frame of four to six weeks. These glycoproteins are suitable for first tests in the laboratory for pilot studies. The long-term system Bryo-Master™ is the subsequent step after Bryo-Speed™ prototyping system.

Bryo-Master™ is employed to create reliable production cell lines which are stable in the long run. These moss cell lines produce the glycoproteins – refined by bryotechnology – in photo bioreactors according to GMP-standards. This guarantees a cost-effective, robust and reliable large scale production for their customers.

greenovation Biotech GmbH ranks first place in the international market with the technological realization of glycoengineering in plants. Their performance spectrum encompasses contract research and development as well as contract manufacturing for the pharmaceutical and the biotech industry. greenovation’s core business are both the production of protein prototypes and desired pharmaceutical proteins on a large scale and the supply of operational production organisms. So far the biotech company has successfully supplied the R&D departments of several pharmaceutical companies with a range of antibodies that are suitable for cancer treatment as well as various other therapeutic proteins.

greenovation uses the small moss Physcomitrella patens as a production system which is perfectly suitable for glycoengineering after it has been appropriately genetically modified. In this process not only the structure of the protein is genetically coded but the attached sugar structure as well. This happens according to a blueprint given by the customer.

Proteins and Antibodies that are created with greenovation technology are characterized by their improved efficiency and lower adverse reaction compared to conventional pharmaceuticals. Cancer therapy with bio pharmaceuticals holds an exceptionally large potential since chemo therapy could be reduced or even completely replaced. The application of biopharmaceutical products embraces almost all medical conditions.

greenovation’s press material in relation to Bryo-SpeedTM and Bryo-MasterTM is available upon request. For more information please visit the re-launched website

Contact greenovation:
Kyrill Schwarz-Herion
greenovation Biotech GmbH
Ndl. Freiburg
Boetzinger Str. 29b
D-79111 Freiburg/ Germany
Tel.: +49 (0)761 47 099-111
Fax: +49 (0)761 47 099-190

A profile of greenovation Biotech
greenovation Biotech GmbH has developed an innovative technology for manufacturing and optimizing complex pharmaceutical proteins in moss cells. The so-called “photo bioreactor” is a safe and cost-effective platform for producing bio pharmaceuticals characterized by an enhanced performance and improved efficiency for example cancer-fighting antibodies. The product can be harvested without cell disruption from a medium consisting of few mineral elements and water. Specific genetic modification permits the adaptation of the protein’s glycosylation pattern. This technology is globally unique. The privately held biotechnology company, headquartered in Heilbronn, Germany, with research facilities in Freiburg, was incorporated in September 1999 as a spin-off of the University of Freiburg. Venture capital investors are L-EigenkapitalAgentur, Karlsruhe, Mediport Venture, Berlin, the SeedGruppe, Tuebingen and Zukunftsfonds, Heilbronn/ Germany.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release greenovation launches Bryo-Speed™ and Bryo-Master™ for the production of therapeutical proteins here

News-ID: 31663 • Views: 1190

More Releases from greenovation Biotech GmbH

greenovation increases investment in GMP-compliant process development for produ …
The primary objective of the investment is the implementation of a stable production platform for the manufacture of glycoproteins for industrial pharmaceutical applications, in accordance with GMP (Good Manufacturing Practice) guidelines - Gregor Mirow succeeds Hans Bodo Hartmann as the new managing director of greenovation Biotech GmbH Heilbronn, Germany – August 28th, 2008 – greenovation Biotech GmbH is investing in an accelerated implementation of its technical production platform in order
Joint process development between Sartorius Stedim Biotech and greenovation Biot … - Major step taken towards process-scale implementation of proprietary bryotechnology developed by greenovation - In demand - Sartorius expertise in fermentation and purification process engineering Heilbronn/ Göttingen – Oktober 12, 2007. Sartorius Stedim Biotech GmbH, headquartered in Goettingen, and greenovation Biotech GmbH in Heilbronn, Germany, agreed to collaborate on the project of process-scale implementation of the innovative, plant-based bryotechnology developed by greenovation. In the past years, greenovation Biotech and Sartorius Stedim
greenovation Biotech GmbH gets first US Patent Granted on Glyco-Engineering Port …
greenovation Biotech GmbH announces the granting of their first US patent in the area of plant-based glyco-engineering. This patent offers wide-ranging protection for the targeted processing of a plant-specific sugar residue. First Patent from a Complete Patent Family Heilbronn – June 20, 2007. Scientists at greenovation Biotech GmbH have been able to build on many years of experience in the area of the design of production strains in moss, in their work

All 4 Releases

More Releases for Germany

Luxury Goods in Germany
Luxury goods enjoyed further positive growth in Germany in 2016, with volume and value sales increases seen in all nine categories covered by Publisher. The highest overall growth was seen in the rather young category of luxury portable consumer electronics, while the slowest growth was reported in the rather old-fashioned category of luxury writing instruments and stationery. Ultimately, the current value growth rate registered across luxury goods in 2016 was
Agrochemicals Market in Germany
ReportsWorldwide has announced the addition of a new report title Germany: Agrochemicals: Market Intelligence (2016-2021) to its growing collection of premium market research reports. The report “Germany: Agrochemicals: Market Intelligence (2016-2021)” provides market intelligence on the different market segments, based on type, active ingredient, formulation, crop, and pest. Market size and forecast (2016-2021) has been provided in terms of both, value (000 USD) and volume (000 KG) in the report. A
Packaged Food in Germany
Summary Retail value sales of packaged food continued to grow in Germany in 2016, as was the case in all years of the review period from 2011 to 2016. The last time a decline took place was in the context of the global economic and financial crisis and the following recession in 2010. In the context of the review period as a whole, the 2016 development was slightly below average, although
Laparoscopes Market 2016 - Stryker (USA), Henke-Sass Wolf (Germany ), Aesculap ( …
Laparoscopic surgery uses a special instrument called the laparoscope. The laparoscope is a long, slender device that is inserted into the abdomen through a small incision. It has a camera attached to it that allows the obstetrician–gynecologist (ob-gyn) to view the abdominal and pelvic organs on an electronic screen. If a problem needs to be fixed, other instruments can be used. These instruments usually are inserted through additional small incisions
MBA - Market Germany
The MBA degree is becoming increasingly more important for career opportunities of young professionals and managers in German- speaking countries. Simultaneously, there is a wide variety of MBA programs and it is strenuous to find the exact program desired. Educationconsult is glad to give you a short overview regarding the German MBA-market. Fact sheet 2009: • 72 University and 130 Universities of Applied Sciences (Fachhochschule) in Germany offer traditional Business Degrees (Diplom,
How safe is Germany?
A few weeks ago, alarmist coverage of a fight which took place during a festival in the small town of Mügeln (Saxony) was featured in newspapers throughout Germany. The incident consisted of a violent confrontation between Indians and Germans, resulting in speculation that the fight was racially motivated. Since then the question of whether Germans are racist or xenophobic has once more been the subject of vigorous discussion. However, Germany is